| Ytd | -17.78% | |
| 1y | -32.17% |
| Open | 14.59 | Prev Close | 14.57 | Low | 14.30 | High | 14.80 | Mkt Cap | 11.16B |
| Vol | 3.84M | Avg Vol | 5.34M | EPS | -1.59 | P/E | N/A | Forward P/E | -12.53 |
| Beta | -1.31 | Short Ratio | 5.67 | Inst. Own | 15.85% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 04-30 | 50-d Avg | 16.86 | 200-d Avg | 17.70 | 1yr Est | 28.39 |
SMMT News
This whale alert can help traders discover the next big trading opportunities. Whales are entities w
Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology c
As a result of such termination, no securities will be sold pursuant to the proposed underwritten pu
US stock futures lower, Nasdaq down 1%. Super Micro shares down 8.6% after announcing $7B offering t
Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") to
https://www.sec.gov/Archives/edgar/data/1599298/000119312526263861/d124326ds3asr.htm
Crude oil surged nearly 8% – its best day since April 2 – after US strikes on Iran and Tehran's
Summit Therapeutics' new ivonescimab trial results showed a survival benefit in lung cancer and
Analysts changed outlook on top names, including SMMT, DAVA. See what others think before buying SMM
Dell, Qualcomm and HP power an AI-fueled rally to send the Dow to record highs. Nasdaq 100 and S&
Bernstein analyst Jeffrey Walch initiates coverage on Summit Therapeutics (NASDAQ:SMMT) with a Un
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Summit Therapeutics (NASDAQ:SMMT) wi
A broad sell-off led by Roblox Corporation, Spotify Technology S.A., and Robinhood Markets, Inc. hig
Stocks traded mixed, with Dow down 0.1% but NASDAQ up 1.06%. Chevron reported mixed Q1 results. Espe
US stocks traded higher, with the Nasdaq up 1%. Dow up 0.05%, Nasdaq up 1.13%, S&P 500 up 0.58%.
Piper Sandler analyst Kelsey Goodwin maintains Summit Therapeutics (NASDAQ:SMMT) with a Neutral a
U.S. stocks hit fresh records as Apple's blowout Q2 powered Big Tech, while crude oil sank 3% on
Summit Therapeutics Inc (NASDAQ:SMMT) shares are plummeting after reporting its first‑quarter financ
US stock futures mixed, SanDisk (NASDAQ: SNDK) shares drop 5.6% in pre-market following strong Q3 re
Twilio Inc (NYSE: TWLO) reported strong Q1 results and raised future sales guidance above estimates,
Tech stocks brushed new record highs during midday Wednesday, as a fresh wave of blockbuster corpora
Large-cap stocks surged last week as catalysts from short squeezes to innovation-driven momentum fue
The S&P 500 and the Nasdaq 100 updated records on Thursday as President Donald Trump announced a
Stifel initiates coverage on Summit Therapeutics (SMMT) with a Buy rating and $45 price target, citi
Top Wall Street analysts changed outlook on top names. See complete rating changes, including upgrad
Stifel analyst Dara Azar initiates coverage on Summit Therapeutics (NASDAQ:SMMT) with a Buy ratin
U.S. stocks rose, with the Dow Jones gaining 350 points on Wednesday. AAR Corp (NYSE: AIR) saw a 10.
U.S. stocks advanced Wednesday as oil prices fell on Iran diplomacy reports. Arm jumped 15%, while T
Jefferies analyst Clara Dong downgrades Summit Therapeutics (NASDAQ:SMMT) from Buy to Hold and lo
U.S. equities traded in mixed territory Friday morning as Wall Street weighed a stark downward revis
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Summit Therapeutics (NASDAQ:SMMT) wi
Summit Therapeutics (NASDAQ:SMMT) reported quarterly losses of $(0.14) per share which missed the an
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Summit Therapeutics (NASDAQ:SMMT) w
Citizens analyst Reni J. Benjamin reiterates Summit Therapeutics (NASDAQ:SMMT) with a Market Outp
The FDA accepted Summit Therapeutics' application for its lung cancer drug ivonescimab, setting
Regencell led last week's large-cap losers as Figma, Atlassian and Trip.com slid on downgrades,
Gold and silver surged to fresh record highs Monday as investors reassessed the Federal Reserve'
Barclays analyst Etzer Darout upgrades Summit Therapeutics (NASDAQ:SMMT) from Underweight to Equa
U.S. small caps climbed to fresh record highs Tuesday as traders nearly fully priced in a Federal Re
Small-cap stocks powered higher Wednesday as expectations for a rate cut next week strengthened afte
Wolfe Research analyst Kalpit Patel initiates coverage on Summit Therapeutics (NASDAQ:SMMT) with
The First Phase III Study Testing Ivonescimab Now Represents the First Statistically Significant OS
Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") to